NAS:CDXS (USA)
Business Description
Codexis Inc
NAICS : 541714
SIC : 8731
200 Penobscot Drive, Redwood, CA, USA, 94063
Compare
Compare
Traded in other countries / regions
4QK.Germany
•
0I0X.UK
•
CDXS.USA
Description
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.95 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -3.9 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.87 | |||||
Beneish M-Score | -1.63 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.8 | |||||
3-Year EBITDA Growth Rate | -10.1 | |||||
3-Year EPS without NRI Growth Rate | -16.3 | |||||
3-Year FCF Growth Rate | -10.4 | |||||
3-Year Book Growth Rate | 34.4 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 6.49 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.48 | |||||
9-Day RSI | 49.31 | |||||
14-Day RSI | 47.83 | |||||
6-1 Month Momentum % | -62.99 | |||||
12-1 Month Momentum % | -70.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.84 | |||||
Quick Ratio | 4.78 | |||||
Cash Ratio | 3 | |||||
Days Inventory | 14.4 | |||||
Days Sales Outstanding | 67 | |||||
Days Payable | 29.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.4 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.21 | |||||
Operating Margin % | -14.85 | |||||
Net Margin % | -14.03 | |||||
ROE % | -11.63 | |||||
ROA % | -8.19 | |||||
ROIC % | -19.31 | |||||
ROC (Joel Greenblatt) % | -34.66 | |||||
ROCE % | -9.96 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.07 | |||||
PB Ratio | 3.43 | |||||
Price-to-Tangible-Book | 3.5 | |||||
EV-to-EBIT | -25.05 | |||||
EV-to-EBITDA | -42.47 | |||||
EV-to-Revenue | 3.72 | |||||
EV-to-Forward-Revenue | 3.73 | |||||
EV-to-FCF | -17.07 | |||||
Price-to-Median-PS-Value | 0.83 | |||||
Price-to-Net-Current-Asset-Value | 7.8 | |||||
Price-to-Net-Cash | 37.91 | |||||
Earnings Yield (Greenblatt) % | -3.99 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CDXS
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 135.016 | ||
EPS (TTM) ($) | -0.3 | ||
Beta | 1.79 | ||
Volatility % | 89.58 | ||
14-Day RSI | 47.83 | ||
14-Day ATR ($) | 0.711279 | ||
20-Day SMA ($) | 7.941 | ||
12-1 Month Momentum % | -70.73 | ||
52-Week Range ($) | 6.15 - 42.01 | ||
Shares Outstanding (Mil) | 65.49 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Codexis Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |